Loading
Eilean Therapeutics designs tablet medicines for blood cancers that are built to keep working when the cancer mutates; its first drug in people targets the faulty JAK2 protein behind polycythaemia vera and myelofibrosis.
Eilean Therapeutics Inc. is a privately held small-molecule oncology company established in 2022, according to the company, focused on pan-variant therapies for haematological malignancies. Its pipeline lists lomonitinib (FLT3/IRAK4, acute myeloid leukaemia), lonitoclax (BCL2), balomenib (menin) and ZE74-0282, a selective inhibitor of mutated JAK2 V617F for polycythaemia vera and myelofibrosis, together with preclinical programmes. Its only registry study sponsored under this name, through the Australian subsidiary Eilean Therapeutics AU Pty Ltd, is a phase 1 safety study of ZE74-0282 in healthy volunteers (NCT07527221), posted on ClinicalTrials.gov in April 2026; it has no registered cancer trial under this sponsor name.
Shares Polycythaemia vera (PV), JAK2.
Shares Polycythaemia vera (PV), JAK2, Primary myelofibrosis.
Shares FLT3, JAK2, Primary myelofibrosis, Small-molecule kinase inhibitors.
Shares FLT3, Acute myeloid leukaemia, Small-molecule kinase inhibitors.
Shares FLT3, Menin, Acute myeloid leukaemia.
Shares FLT3, Acute myeloid leukaemia.
Shares FLT3, Acute myeloid leukaemia, Small-molecule kinase inhibitors.
Shares JAK2, Primary myelofibrosis, Small-molecule kinase inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/